.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The MAGIC trial was one of the landmark studies that changed the management of resectable gastroesophageal cancer. It compared surgery alone with perioperative chemotherapy followed by surgery and postoperative chemotherapy in patients with operable gastric and lower esophageal cancers. Patients receiving perioperative chemotherapy had improved progression-free and overall survival compared with surgery alone. The study demonstrated why systemic treatment should not necessarily be deferred until after an operation: chemotherapy can treat occult disease early, potentially shrink the primary tumor and improve the chances of completing planned multimodality therapy. Although modern regimens and staging have evolved, the trial established the principle that surgery should be integrated into a broader oncological strategy rather than considered an isolated intervention. For contemporary practice, it also reinforces the importance of multidisciplinary planning before surgery, because nutritional status, staging, resectability, medical fitness and postoperative treatment all influence the final pathway. The results underpin the continued use of perioperative chemotherapy strategies in appropriately selected resectable gastroesophageal cancers.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The MAGIC trial was one of the landmark studies that changed the management of resectable gastroesophageal cancer. It compared surgery alone with perioperative chemotherapy followed by surgery and postoperative chemotherapy in patients with operable gastric and lower esophageal cancers. Patients receiving perioperative chemotherapy had improved progression-free and overall survival compared with surgery alone. The study demonstrated why systemic treatment should not necessarily be deferred until after an operation: chemotherapy can treat occult disease early, potentially shrink the primary tumor and improve the chances of completing planned multimodality therapy. Although modern regimens and staging have evolved, the trial established the principle that surgery should be integrated into a broader oncological strategy rather than considered an isolated intervention. For contemporary practice, it also reinforces the importance of multidisciplinary planning before surgery, because nutritional status, staging, resectability, medical fitness and postoperative treatment all influence the final pathway. The results underpin the continued use of perioperative chemotherapy strategies in appropriately selected resectable gastroesophageal cancers.
Yesterday
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
